February 9, 2022 5:13pm
To our portfolio favor today
The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares trading down -$0.61 (was as low as -$1.09) with 4,030 shares traded after Tuesday’s +$0.05 with 1,293 shares traded and Monday’s +$0.55 with 2,311 shares traded,
Pre-open Indications: 6 Hits, 2 Miss
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
Who else is tracking a broad grouping of cell and gene therapy equities – with facts supported by real numbers?
The Dow closed UP +305.28 points (+0.86%); the S&P closed UP +65.64 points (+1.45%) while the Nasdaq closed UP +295.92 points (+2.08%)
Henry’omics:
Indexes rose on Wednesday as investors digested another batch of corporate earnings.
The Nasdaq has gained roughly 8% from its recent low on Jan. 27 after falling into correction territory earlier this year.
RegMed Investors’ (RMi) pre-open: “closer and closer, come sector earnings” … https://www.regmedinvestors.com/articles/12293
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Wednesday opened positive at 31 up/1 downs, 2 flats and 1 acquired, stayed positive at the mid-day at 32/1, 1 flat and 1 acquired, ending with a positive close of 31/3 and 1 acquired;
Pre-open indications: 6 Hits < Intellia Therapeutics (NTLA +$4.57), Editas Medicine (EDIT +$1.06); Sell into Strength: Ionis Pharmaceuticals (IONS +$1.34), Sage Therapeutics (SAGE +$1.56), CRISPR Therapeutics (CRSP +$4.00), Biostage (BSTG -$0.61)> 2 MISS <Applied Genetic Technologies (AGTC +$0.16), Fate Therapeutics (FATE +$1.04)>
The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares trading down -$0.61 (was as low as -$1.09) with 4,030 shares traded after Tuesday’s +$0.05 with 1,293 shares traded after Monday’s +$0.55 with 2,311 shares traded, Friday’s +$0.22 with 305 shares traded, Thursday’s flat ($0.00) with 3 shares traded, Wednesday’s down -$0.53 with 502 shares traded, Tuesday’s +$0.40 with 1,088 shares after Monday’s 11 shares traded after Friday’s +$0.05 with 3,225 shares traded after Thursday’s +$0.24 with 10,073 - double the mornings 5,030 shares traded after last Wednesday’s diving to -$0.00 with 7,796 shares trading after appreciating +$0.35 (after dropping mid-day -$0.07 – such sarcasm after miraculous jump) and the previous Tuesday’s +$0.31 with 2,794 shares traded.
Key Metrics:
- Wednesday - Sector volume was LOW with 9 of the 31-upside having higher than the 3-month average volume with LOW volume of 1 of 3-downside having higher than the 3-month average volume
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Wednesday the IBB closed up +4.65% and XBI closed up +2.70%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Wednesday was down -1.48 points or -6.90% at 19.96
Jumping with share pricing momentum (10 of 31):
- Ultragenyx (RARE +$5.68),
- Intellia Therapeutics (NTLA +$4.57),
- CRISPR Therapeutic (CRSP +$4.00),
- Alnylam Pharmaceuticals (ALNY +$3.76),
- ReNeuron (RENE.L +$3.70),
- Vericel (VCEL +$2.00),
- Sage Therapeutics (SAGE +$1.56),
- Global Blood Therapeutics (GBT +$1.41),
- Fate Therapeutics (FATE +$1.40),
- BioLife Solutions (BLFS +$1.36),
Hammered in today’s market (3 of 3):
- Biostage (BSTG -$0.61 after Tuesday’s +$0.05),
- Adverum Biotechnologies (ADVM -$0.02),
- Pluristem (PSTI -$0.01),
Closing Flat:
- 1- Stemline Therapeutics (STML) – acquired
February, Q1/2022:
- Wednesday closed positive with 31 incliner, 3 decliners and 1 acquired
- Tuesday closed negative with 14 incliners, 19 decliners, 1 flat and 1 acquired
- Monday (2/7) closed positive with 29 incliners, 4 decliners, 1 flat and 1 acquired
The BOTTOM LINE: The sector feels the gain after the pain again as share pricings bolted as I had stated “the algorithms are warming-up to pitch” in the a.m. post.
Some of the most equities that were leading in Monday’s trading were trampled in Tuesday’s session.
The roller-coaster …
Wednesday’s “jumpers” were Ultragenyx Pharmaceuticals (RARE), CRISPR Therapeutics (CRSP), Intellia therapeutics (NTLA) and ReNeuron (RENE.L) with Biostage (BSTG) diving following …
Tuesday’s ReNeuron (RENE.L) race to the upside after feeling the grit of laying in the dirt of the downside while trading up again were Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE and Global Blood Therapeutics (GBT) while the few down-trodden were Intellia therapeutics (NTLA) after
Monday’s up and Editas Medicine (EDIT) and CRISPR Therapeutics (CRSP), along with losers BioLife Solutions (BLFS) and Precigen (PGEN).
Investors will be watching earnings reports this week; Q4 and end-of-year earnings are about to be made aware of” more than even I thought.
• Ultragenyx Pharmaceuticals (RARE) - 2/10, Thursday
• Alnylam Pharmaceuticals (ALNY) reports Q4 and FY21 on Thursday, 2/10
• Applied Genetic Technologies (AGTC) on Monday, 2/14
• AxoGen AXGN) – 2/22, Tuesday
Algorithms, hedge funds and traders continue to punish and … then push the cell and gene therapy stocks as valuations “creep” up.
WHY do I keep analyzing Biostage (BSTG): I WAS there to experience the lack of investor prerogatives and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
